本文選題：慢性鼻-鼻竇炎 + 鼻淵舒口服液　； 參考：《成都中醫(yī)藥大學(xué)》2016年碩士論文

【摘要】：研究目的本課題旨在利用16SrDNA分析鼻腔菌群結(jié)構(gòu),探討鼻淵舒口服液作為清膽泄熱法的代表方在治療膽腑郁熱證慢性鼻-鼻竇炎方面的作用機(jī)制。研究方法將符合標(biāo)準(zhǔn)的12例膽腑郁熱型慢性鼻-鼻竇炎患者及9例健康正常人納入組取其中鼻道分泌物,并予以慢性鼻-鼻竇炎病人組華神集團(tuán)生產(chǎn)的鼻淵舒口服液,每日3次,每次1支,2周治療結(jié)束后再次取同側(cè)中鼻道分泌物。利用16SrDNA克隆文庫(kù)測(cè)序分析法檢測(cè)各組鼻腔細(xì)菌菌群結(jié)構(gòu)表達(dá)情況。最后經(jīng)統(tǒng)計(jì)學(xué)分析,得出結(jié)論。研究結(jié)果慢性鼻-鼻竇炎病人組中樣品最大shannon指數(shù)為1.406,Simpson指數(shù)最小為0.213,服用鼻淵舒口服液后的鼻竇炎患者組中最大shannon指數(shù)為0.453,simpson指數(shù)最小為0.103,健康正常人的shannon指數(shù)最大為0.952,Simpson指數(shù)最小為0.15。慢性鼻-鼻竇炎患者組的鼻腔菌群多樣性較健康正常人高,服用鼻淵舒口服液治療后的慢性鼻-鼻竇炎患者鼻腔菌群多樣性有所降低,較健康正常人低。鼻竇炎病人組的菌群結(jié)構(gòu)為Staphylococcaceae占67.53%, Enterobacteriaceae占22.34%,Streptococcaceae占5.87%,Pseudomonadaceae占0.91%,Oxalobacteraceae占0.28%,Xanthomonadaceae占0.21%。服用鼻淵舒治療后的鼻竇炎病人組菌群比例為Enterobacteriaceae占95.28%,Staphylococcaceae占3.24%、Streptococcaceae占0.93%,其余細(xì)菌均未達(dá)到0.1%。健康正常人組菌群比例為Staphylococcaceae占96.12%,Enterobacteriaceae 占 0.85%, Streptococcaceae占0.51%,其余細(xì)菌均未達(dá)到0.1%。結(jié)論①慢性鼻-鼻竇炎患者較正常健康人鼻腔菌群多樣性高,二者菌群比例有所不同,但優(yōu)勢(shì)菌都為Staphylococcaceae,推測(cè)慢性鼻-鼻竇炎發(fā)病是條件致病菌引起的。②服用鼻淵舒口服液治療后的慢性鼻-鼻竇炎患者的菌群多樣性減少,優(yōu)勢(shì)菌群的科屬發(fā)生改變,推測(cè)鼻淵舒口服液治療慢性鼻-鼻竇炎的作用機(jī)制在于改變鼻腔內(nèi)環(huán)境,調(diào)整鼻腔菌群結(jié)構(gòu),抑制條件致病菌生長(zhǎng)。
[Abstract]:Objective to investigate the mechanism of Biyuanshu oral liquid in treating chronic rhinosinusitis with chronic rhinosinusitis by 16SrDNA. Methods 12 patients with chronic rhinosinusitis and 9 healthy controls were included in the study group. The nasal secretions were collected from the patients with chronic rhinosinusitis and were treated with Biyuanshu oral liquid produced by Huaxin Group, a group of patients with chronic rhinosinusitis. After 2 weeks of treatment, the secretion of middle nasal canal was collected again 3 times a day. The expression of bacterial flora in nasal cavity was detected by sequencing analysis of 16SrDNA clone library. Finally, by statistical analysis, draw a conclusion. Results the maximum shannon index of samples in patients with chronic rhinosinusitis was 1.406 and the minimum was 0.213. The maximum shannon index of sinusitis patients after taking Biyuanshu oral liquid was 0.453 and the minimum was 0.103. The shannon index of healthy people was the highest. Dawei 0.952 Simpson index minimum 0.15. The diversity of nasal microflora in patients with chronic rhinosinusitis was higher than that in healthy subjects, and the diversity of nasal flora in patients with chronic rhinosinusitis was lower than that in healthy subjects after treatment with Biyuanshu oral liquid. In sinusitis group, the microflora structure was Staphylococcaceae (67.53), Enterobacteriaceae (22.34) and Streptococcaceae (5.87). Pseudomonadaceae was 0.91% and Oxalobacteraceae was 0.280.28%, Xanthomonadaceae was 0.21%. The proportion of bacteria in patients with sinusitis treated with Biyuanshu was 95.2828. Staphylococcaceae was 3.24 and Streptococcaceae was 0.93.The other bacteria did not reach 0.1. In healthy people, the proportion of bacteria in Staphylococcaceae was 96.12, 0.85 in Enterobacteriaceae, 0.51in Streptococcaceae, none of the other bacteria had reached 0.1. Conclusion (1) the diversity of nasal flora in patients with chronic rhinosinusitis is higher than that in normal controls. But the dominant bacteria were Staphylococcaceae. it was speculated that the incidence of chronic rhinosinusitis was caused by opportunistic bacteria. 2. The diversity of bacteria in patients with chronic rhinosinusitis treated with Biyuanshu oral solution was decreased, and the family and genus of dominant bacteria were changed. It is inferred that the mechanism of Biyuanshu oral liquid in treating chronic rhinosinusitis lies in changing the intranasal environment, adjusting the structure of nasal flora and inhibiting the growth of conditioned pathogens.
【學(xué)位授予單位】：成都中醫(yī)藥大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2016
【分類號(hào)】：R276.1

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 ;鼻淵舒口服液(膠囊)全國(guó)臨床應(yīng)用10周年有獎(jiǎng)?wù)魑耐ㄖ猍J];中華耳鼻咽喉科雜志;2004年08期

2 ;關(guān)于舉行鼻淵舒口服液(膠囊)全國(guó)臨床應(yīng)用10周年有獎(jiǎng)?wù)魑牡耐ㄖ猍J];中國(guó)中西醫(yī)結(jié)合耳鼻咽喉科雜志;2004年06期

3 古麗波斯坦 ,古麗菲亞;鼻淵舒口服液在鼻疾手術(shù)后的應(yīng)用[J];新疆中醫(yī)藥;2005年03期

4 本刊編輯部;;鼻淵舒口服液全國(guó)臨床應(yīng)用10周年有獎(jiǎng)?wù)魑念C獎(jiǎng)儀式在武漢舉行[J];中華耳鼻咽喉頭頸外科雜志;2005年12期

5 ;關(guān)于舉行鼻淵舒口服液(膠囊)全國(guó)臨床應(yīng)用10周年有獎(jiǎng)?wù)魑牡耐ㄖ猍J];中國(guó)中西醫(yī)結(jié)合耳鼻咽喉科雜志;2005年01期

6 鄭桂香,吳謙霞,郭桂萍;鼻淵舒口服液在鼻內(nèi)窺鏡鼻竇手術(shù)后的療效觀察[J];實(shí)用醫(yī)技;2001年05期

7 殷曉東;鼻淵舒口服液對(duì)功能性鼻內(nèi)窺鏡手術(shù)后術(shù)腔粘膜轉(zhuǎn)歸的影響[J];實(shí)用臨床醫(yī)藥雜志;2005年08期

8 袁曉陽(yáng);;鼻淵舒口服液治療兒童慢性鼻竇炎臨床觀察[J];中國(guó)中西醫(yī)結(jié)合耳鼻咽喉科雜志;2006年03期

9 劉文義;;鼻淵舒口服液治療慢性化膿性鼻竇炎186例臨床觀察[J];現(xiàn)代醫(yī)藥衛(wèi)生;2006年15期

10 董淑霞;衛(wèi)元峽;林新;;鼻淵舒口服液治療鼻竇炎120例[J];陜西中醫(yī);2007年08期

相關(guān)會(huì)議論文 前3條

1 劉敏;張大錚;張勤修;;口服鼻淵舒口服液在慢性鼻-鼻竇炎鼻內(nèi)窺鏡術(shù)圍手術(shù)期的臨床療效及安全性評(píng)價(jià)[A];第十次全國(guó)中醫(yī)藥傳承創(chuàng)新與發(fā)展學(xué)術(shù)交流會(huì)暨第二屆全國(guó)中醫(yī)藥博士生優(yōu)秀論文頒獎(jiǎng)會(huì)議論文集[C];2011年

2 李秀敏;;鼻淵舒口服液治療慢性化膿性鼻竇炎的臨床觀察(摘要)[A];第三屆第四次全國(guó)中西醫(yī)結(jié)合耳鼻咽喉科學(xué)術(shù)會(huì)論文匯編[C];2002年

3 張磊;;鼻淵舒口服液在鼻內(nèi)鏡術(shù)后鼻腔沖洗的療效分析[A];中華中醫(yī)藥學(xué)會(huì)耳鼻喉科分會(huì)第十六次全國(guó)學(xué)術(shù)交流會(huì)論文摘要[C];2010年

相關(guān)重要報(bào)紙文章 前1條

1 北京市和平里醫(yī)院耳鼻喉科副主任醫(yī)師 邵秀玲;鼻炎微波術(shù)后護(hù)理[N];醫(yī)藥養(yǎng)生保健報(bào);2006年

相關(guān)碩士學(xué)位論文 前8條

1 劉奕彤;利用16SrDNA分析清膽泄熱法治療慢性鼻—鼻竇炎患者的鼻腔菌群結(jié)構(gòu)變化[D];成都中醫(yī)藥大學(xué);2016年

2 劉亞婷;慢性鼻—鼻竇炎的細(xì)菌生物膜表達(dá)及鼻淵舒口服液對(duì)人分泌型免疫球蛋白A的調(diào)節(jié)作用[D];成都中醫(yī)藥大學(xué);2016年

3 趙廣富;鼻淵舒口服液灌注內(nèi)窺鏡鼻竇術(shù)后的療效觀察[D];湖北中醫(yī)學(xué)院;2008年

4 許必芳;鼻淵舒口服液對(duì)治療實(shí)驗(yàn)性急性鼻竇炎大鼠作用機(jī)理的研究[D];成都中醫(yī)藥大學(xué);2005年

5 袁曉輝;鼻淵舒口服液對(duì)急性鼻竇炎大鼠炎癥因子影響的研究[D];成都中醫(yī)藥大學(xué);2005年

6 劉敏;口服鼻淵舒口服液在慢性鼻—鼻竇炎鼻內(nèi)窺鏡術(shù)圍手術(shù)期的臨床療效及安全性評(píng)價(jià)[D];成都中醫(yī)藥大學(xué);2010年

7 楊林林;鼻淵舒口服液對(duì)慢性鼻竇炎COX-2及MMP-2表達(dá)影響研究[D];成都中醫(yī)藥大學(xué);2014年

8 張進(jìn)玲;鼻竇清合劑治療脾胃濕熱型兒童鼻竇炎的臨床研究[D];山東中醫(yī)藥大學(xué);2013年

，

本文編號(hào)：1831022